FDA's kratom liver toxicity warning names a serious safety concern, not a prediction that every user will develop liver injury. Liver toxicity means harm to the liver. FDA warns consumers not to use kratom because of serious risks. Its separate OPMS Black Liquid Kratom alert names one product. For adults and loved ones in GA, three things differ: the broad warning, product reports, and personal care needs.
What does FDA warn about kratom and liver injury?
FDA includes liver toxicity among the serious harms behind its warning against kratom use. The warning extends beyond one brand. When addiction treatment is matched to a person's needs, liver concerns still call for separate physical health care. An addiction program name alone does not show that it provides liver care.
FDA also names seizures and substance use disorder among its serious concerns. Substance use disorder means a pattern of use that causes significant problems. These are distinct concerns, not different names for liver injury. FDA's broad warning does not say that each person who uses kratom will develop these problems.
The agency says no drug products with kratom or its known active compounds are legally marketed in the United States. This applies to both prescription and over-the-counter drugs. It also says kratom is not lawfully marketed as a dietary supplement. It cannot lawfully be added to conventional foods. These are FDA's conclusions about product marketing, not findings about the cause of one person's illness.
A bottle on a store shelf can look familiar and reassuring. Yet being sold does not mean a product has FDA approval as a medicine. The agency warns about a common assumption: kratom is safe because it comes from a plant. Being sold online or in stores does not show safety either. FDA rejects that basis for assuming safety.
FDA describes a formal route for studying a possible kratom-based medicine. A company could submit a new drug application. FDA would then review evidence for safety and benefit in a specific condition. That process is different from a seller claiming that a product helps a health problem. Those questions remain open. FDA continues to warn against kratom for medical treatment.
What does the OPMS Black Liquid Kratom alert actually say?
The OPMS alert tells consumers not to consume that named product. It describes serious reports after use, without identifying them as liver injuries. A product warning may matter to individual addiction treatment planning, while care for physical health concerns remains a separate part of the person's needs.
The alert is dated July 26, 2024. FDA says it received a report of a person who died after using OPMS Black Liquid Kratom. It describes that report as one of many serious events reported after use of the product. The notice does not state that liver injury caused the death.
Other effects listed in the OPMS reports include:
- Withdrawal symptoms and addiction
- Digestive issues and skin problems
- Increased anxiety and aggressive behavior
- Lack of energy and trouble focusing
FDA says the product label lists mitragynine and 7-hydroxymitragynine, often called 7-OH. These are compounds found in kratom. The label description in the alert does not give their amounts. It also does not assign the reported events to either compound.
| FDA material | What it establishes | Important boundary |
|---|---|---|
| Broad kratom warning | FDA names liver toxicity among serious risks. | It does not state how often liver injury occurs. |
| OPMS product alert | FDA advises against the named liquid product. | The described reports are not identified as liver injuries. |
| Research overview | FDA describes limited well-designed human research. | Animal findings and human reports are different evidence types. |
The named-product warning does not cancel FDA's broader concern. Nor does it establish that every kratom product has the same contents or effects. The two statements have different scopes. One warns about kratom use overall. The other addresses reports involving a specific liquid product.
Can reports prove what caused liver injury or how common it is?
No. A report can flag a possible problem without proving its cause or showing how often it occurs. FDA's kratom safety information does not provide a liver-injury rate. Choosing suitable addiction care and coordinating medical care depend on the person's assessed needs, not a risk score drawn from these reports.
An adverse event is an unwanted health event reported after use of a product. “After” describes timing. It does not, by itself, prove “because of.” The OPMS alert describes reports and an investigation. It does not present a controlled study that isolates the product's role.
To measure frequency, a count of reports alone is not enough. A sound rate needs a suitable count of people exposed. It also needs a clear way to identify the outcome. The FDA overview gives no such calculation for liver injury. Its national estimate of kratom use cannot turn separate safety reports into an injury rate.
Other substance use can complicate the picture. FDA says other drugs were usually involved in rare deaths associated with kratom. Kratom’s role was unclear. This statement concerns deaths associated with kratom. It is not evidence that another drug caused a particular liver injury, or that kratom played no part.
Research types also matter. FDA notes published animal studies with kratom extracts. Few published reports come from well-designed studies that gave kratom to people. An animal experiment is not a human case report. Neither should be presented as a measured liver-injury rate for consumers. FDA identifies the need for more research rather than treating these sources as interchangeable.
Even human study results need a clear product context. FDA says findings must be weighed against the many different kratom-related products for sale. A study of botanical kratom does not automatically answer every question about a liquid extract or another formulation. That product variation matters to how research is interpreted.
Reports still serve a purpose: FDA says it continually evaluates them and encourages consumers and health professionals to report suspected reactions. Safety monitoring can prompt a public warning even when the evidence cannot settle every causal question. Uncertainty about a rate is not evidence that a concern is harmless.
Does stronger 7-OH activity mean greater liver toxicity?
No liver-risk ranking follows from the FDA description of 7-OH activity. It concerns how the compound acts at certain brain receptors, not a comparison of liver injury. Neither substance-specific addiction care nor physical health planning should treat stronger brain activity as proof of greater harm to the liver.
FDA describes 7-hydroxymitragynine as a small natural part of kratom leaves. It makes up less than two percent of their total alkaloid content. Alkaloids are a group of plant compounds. This natural-leaf figure describes the share of those compounds, not the amount in every finished product.
FDA says 7-OH has greater potency than mitragynine at mu-opioid receptors. These receptors are parts of cells through which opioids act. The comparison describes activity at those receptors. FDA does not use it to rank the compounds by liver harm. Greater potency in one respect does not supply a missing liver comparison.
The OPMS label's mention of both compounds does not resolve that gap. The product alert does not identify either ingredient as the cause of a reported liver injury. It would therefore go beyond the evidence to say that 7-OH explains the liver-toxicity warning.
Liver harm is also not FDA's only concern. The broader warning names seizures and substance use disorder. Still, these statements are not a complete organ-by-organ account. They do not compare kratom with kava or identify the drug most toxic to the liver. Those rankings cannot be drawn from this evidence.
How should liver concerns and addiction support be handled?
Possible liver injury needs medical assessment, separate from choosing an addiction program. Physical health and addiction care coordination keeps those roles clear. River City Recovery provides adult outpatient addiction support in Columbus, GA, not liver treatment. A concern after kratom use should not be treated as a diagnosis or routed only through program admissions.
The FDA kratom information warns about liver toxicity but does not give a specific liver-injury symptom list. It also gives no personal instructions for changing prescription medicines. A public warning cannot decide whether a person's symptoms involve the liver or which treatment that person needs.
Addiction concerns can deserve attention alongside physical health concerns. FDA describes observed cases of kratom-related substance use disorder. The reported patterns included:
- Using more than intended
- Continuing use longer than intended
- Having cravings for kratom
- Continuing use despite harm to health or daily life
These patterns do not prove liver injury. They describe a different concern that can belong in an addiction assessment. FDA also reports tolerance: more was needed for the same effect. It reports physical dependence, including withdrawal when use stopped. Those findings are not a home withdrawal plan.
Reporting and care have separate roles, too. FDA encourages reports through MedWatch or its Safety Reporting Portal. A report helps safety monitoring. It does not arrange medical care. For outpatient addiction support, call River City Recovery at 706-617-4970 or contact the team. That conversation does not replace medical assessment or guarantee a particular service.
Frequently asked questions
Does FDA's warning mean all kratom causes liver injury?
No. FDA names liver toxicity among the serious risks behind its warning against kratom use. It does not say every user will develop liver injury or that every product has the same effects. The warning identifies a serious concern, but it does not provide a liver-injury rate or predict one person's outcome. Sources: FDA; FDA.
Does the OPMS alert describe confirmed liver-injury cases?
The alert describes serious events reported after OPMS Black Liquid Kratom use, including a death report. It does not identify those events as liver injuries or say liver injury caused the death. FDA advises consumers not to consume that named product. Its broader kratom warning separately includes liver toxicity. Sources: FDA; FDA.
Does 7-OH's greater potency show that it is worse for the liver?
No such comparison follows from FDA's statements. The agency describes stronger activity at certain brain receptors, not greater liver harm. It also describes 7-OH as a minor part of natural kratom leaves. Neither fact shows the liver effects of a finished product. Neither explains what caused a person’s illness. Sources: FDA; FDA.
Why can't adverse-event reports show how common liver injury is?
A report records a suspected problem after product use. It does not by itself establish the cause. Measuring frequency also requires a suitable count of exposed people and a clear way to identify cases. FDA's kratom information does not provide that calculation for liver injury, so the reports cannot supply a reliable rate. Sources: FDA; FDA.
Does outpatient addiction support replace medical assessment for liver concerns?
No. Medical assessment addresses a possible liver problem, while addiction support addresses substance-related needs. River City Recovery provides adult outpatient addiction services in Columbus, GA, not liver treatment. A person may have both kinds of concerns. An addiction program cannot replace medical care or explain what caused an illness. Sources: FDA; FDA; RiverCityRecovery.
By Tim Francis, SUD Content Specialist. Reviewed by clinical staff.
